Starpharma picks up patent for dendrimers

Aug. 8, 2002 — Starpharma Pooled Development Ltd. said it has received a U.S. patent for nanotech-based cancer treatment products.

The patent provides broad rights related to dendrimer-based products that inhibit angiogenesis, a key process in the growth and spread of cancerous tumors. Dendrimers are synthetic products built on the nanoscale that are being designed in microscopic capsules for drug delivery.

Starpharma, based in Australia, is developing dendrimers for treatment of a range of major diseases.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.